7-butoxy-2-(3,4-dimethoxyphenyl)-5-hydroxychroman-4-one | 1420071-83-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 7-butoxy-2-(3,4-dimethoxyphenyl)-5-hydroxychroman-4-one
• CAS: 1420071-83-5
• 化学式: C₂₁H₂₄O₆
• 分子量: 372.418
• InChiKey: CCSPXDZIHGSYMT-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.29
• 重原子数：
  27.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  74.22
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  橙皮甙 在 硫酸 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 7.5h， 生成 7-butoxy-2-(3,4-dimethoxyphenyl)-5-hydroxychroman-4-one
  参考文献：
  名称：

  Synthesis and anti-hyperglycemic activity of hesperidin derivatives

  摘要：

  A series of hesperidin derivatives were prepared and identified by IR, H-1 NMR, and MS spectra. These compounds were evaluated in vitro and in vivo based on alpha-glucosidase inhibition, glucose consumption of HepG2 cells, and blood glucose level in streptozotocin-induced diabetic mice. The results revealed that all the compounds exhibited anti-hyperglycemic activities. The inhibition at 10 (3) M of compounds 3 and 7a on alpha-glucosidase were 55.02% and 53.34%, respectively, as compared to 54.80% by acarbose. Treated by compound 3 and the reference drug metformin, glucose consumption of HepG2 cell were 1.78 and 2.11 mM, respectively. After the streptozotocin-induced diabetic mice were oral administrated with compound 3 at 100 mg kg (1) d (1) for 10 days, the blood glucose level of 3 treated mice (13.23 mM, P<0.05) showed significant difference when compared to model control (23.03 mM). Thus, compound 3 exhibited promising anti-hyperglycemic activity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.049

文献信息

• Synthesis and anti-hyperglycemic activity of hesperidin derivatives
  作者：Baoshun Zhang、Tingting Chen、Zhu Chen、Mingxue Wang、Dengyu Zheng、Jinfeng Wu、Xiaofei Jiang、Xuegang Li

  DOI：10.1016/j.bmcl.2012.09.049

  日期：2012.12

  A series of hesperidin derivatives were prepared and identified by IR, H-1 NMR, and MS spectra. These compounds were evaluated in vitro and in vivo based on alpha-glucosidase inhibition, glucose consumption of HepG2 cells, and blood glucose level in streptozotocin-induced diabetic mice. The results revealed that all the compounds exhibited anti-hyperglycemic activities. The inhibition at 10 (3) M of compounds 3 and 7a on alpha-glucosidase were 55.02% and 53.34%, respectively, as compared to 54.80% by acarbose. Treated by compound 3 and the reference drug metformin, glucose consumption of HepG2 cell were 1.78 and 2.11 mM, respectively. After the streptozotocin-induced diabetic mice were oral administrated with compound 3 at 100 mg kg (1) d (1) for 10 days, the blood glucose level of 3 treated mice (13.23 mM, P<0.05) showed significant difference when compared to model control (23.03 mM). Thus, compound 3 exhibited promising anti-hyperglycemic activity. (C) 2012 Elsevier Ltd. All rights reserved.